Exact Sciences Corp. (NASDAQ:EXAS) shares rose 4% during trading on Wednesday . The stock traded as high as $12.33 and last traded at $12.33, with a volume of 1,748,326 shares traded. The stock had previously closed at $11.86.

EXAS has been the subject of several recent analyst reports. BTIG Research reiterated a “buy” rating on shares of Exact Sciences Corp. in a report on Tuesday, May 10th. Craig Hallum reiterated a “buy” rating on shares of Exact Sciences Corp. in a report on Wednesday, June 22nd. Jefferies Group restated a “buy” rating and set a $13.00 price target on shares of Exact Sciences Corp. in a report on Wednesday, June 15th. Zacks Investment Research upgraded shares of Exact Sciences Corp. from a “hold” rating to a “buy” rating and set a $8.25 price target for the company in a report on Tuesday, April 26th. Finally, Robert W. Baird restated an “outperform” rating and set a $15.00 price target (up from $12.00) on shares of Exact Sciences Corp. in a report on Wednesday, June 22nd. Eight research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $10.17.

The company’s 50-day moving average price is $8.45 and its 200-day moving average price is $7.20. The stock’s market cap is $1.21 billion.

Exact Sciences Corp. (NASDAQ:EXAS) last announced its quarterly earnings results on Tuesday, May 3rd. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.03. During the same period last year, the company earned ($0.40) earnings per share. The company earned $14.80 million during the quarter, compared to the consensus estimate of $15.17 million. The business’s revenue was up 244.2% compared to the same quarter last year. On average, equities research analysts forecast that Exact Sciences Corp. will post ($2.00) EPS for the current year.

Several institutional investors have modified their holdings of EXAS. US Bancorp DE raised its position in shares of Exact Sciences Corp. by 2.3% in the fourth quarter. US Bancorp DE now owns 229,594 shares of the company’s stock valued at $2,119,000 after buying an additional 5,109 shares in the last quarter. OppenheimerFunds Inc. raised its position in shares of Exact Sciences Corp. by 455.5% in the fourth quarter. OppenheimerFunds Inc. now owns 2,777,430 shares of the company’s stock valued at $25,636,000 after buying an additional 2,277,430 shares in the last quarter. California State Teachers Retirement System raised its position in shares of Exact Sciences Corp. by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 177,702 shares of the company’s stock valued at $1,640,000 after buying an additional 2,809 shares in the last quarter. Finally, Eagle Asset Management acquired a new position in shares of Exact Sciences Corp. during the third quarter valued at about $39,880,000.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.